AMRX vs TXT · P/E 44, rev $1.52B vs P/E 19, rev $7.52B
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) versus Textron Inc (TXT) — a side-by-side from cached financials, not a winner call.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Textron Inc (TXT) is a aerospace & defense company listed on US.
Latest reported AMRX revenue for 2026-06-30 was $1.52B. Net income was $119.9M. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
Latest reported TXT revenue for 2026-07-04 was $7.52B. Net income was $468.0M. TXT currently screens at market cap $14.85B and trailing P/E 18.5.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. TXT currently screens at market cap $14.85B and trailing P/E 18.5.
Not investment advice. Open the AMRX and TXT stock pages for the full models.
Not investment advice.